Retransmission of the press release that was published, with the associated MAR label, on April 1st, 2026 at 16:50.

Scandinavian ChemoTech’s Animal Care continues its strong commercial momentum, delivering its best first quarter in the company’s history in Q1 2026, with sales amounting to approx. 299,000 USD compared to approx. 235,000 USD in Q1 2025, a growth of 27%. This performance marks a strong start to 2026 and reinforces the positive growth trajectory established throughout 2025. It also demonstrates the increasing market acceptance of the company’s veterinary oncology offering and the continued success of its commercial strategy.

Traditionally, the first quarter tends to be seasonally softer, particularly among larger veterinary groups, where capital expenditure budgets are often not yet fully released for purchasing early in the year. Against that backdrop, this record Q1 performance is especially encouraging and highlights the strength of demand for Animal Care’s vetIQure™ system and TSE treatments.

A key driver behind this development is the growing recognition of the clinical and financial benefits of TSE treatments, combined with strong customer satisfaction and increasing confidence from both new and existing customers. The company continues to see a healthy mix of system placements and recurring treatment kit demand, supporting a more scalable and predictable revenue base.

“Delivering our best Q1 ever is a very strong way to begin 2026” says Mohan Frick, CEO of Scandinavian Chemotech AB. “What makes this result even more meaningful is that the first quarter is normally a softer period for our business, as many larger veterinary groups are still waiting for capital expenditure budgets to be released. Seeing this level of performance despite that seasonal pattern gives us confidence that demand is strengthening and that we are entering the year with very good momentum.”

With this strong opening to 2026, ChemoTech’s Animal Care operation is well-positioned for continued progress during the year. The company remains focused on sustainable growth, expanding clinical adoption, and building further momentum toward profitability.